6
total announcements
NATCOPHARM.NS · 15 min delayed
Natco Pharma Limited
Natco Pharma Limited has received tentative approval from the US FDA for its Olaparib tablets, a generic version of AstraZeneca's Lynparza, for the indication in the approved labelling.
Natco Pharma Limited
Natco Pharma Limited has completed the acquisition of an additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited, increasing its shareholding from 35.75% to 49%. The acquisition was completed through Natco Pharma South Africa Proprietary Limited, Natco's wholly owned subsidiary in South Africa.
Natco Pharma Limited
Natco Pharma Limited has informed the Exchange about actions taken or orders passed under the APGST & CGST Act, 2017, raising a tax demand of Rs. 21,34,729/-, interest of Rs 17,17,806/- and penalty of Rs.21,34,729/-.
Natco Pharma Limited
Natco Pharma Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, confirming the dematerialization of securities and updating the records of the company.
Natco Pharma Limited
Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026, where the Board of Directors approved to acquire additional shareholding in Adcock Ingram Holdings Proprietary Limited, increasing its stake from 35.75% to 49%. The acquisition valued at ₹ 1,069 crores will take NATCO's shareholding in Adcock Ingram from 35.75% to 49%. Adcock Ingram has delivered a topline of US$ 423 million with an EBITDA of ~US$ 59 million for the period ending 9 months on March 31, 2026.
Natco Pharma Limited
Natco Pharma Limited has announced a change in management with Mr. Gnanadeva Chalapathy Gudipati being designated as Senior Vice President - Analytical Research & Development and Mr. Madhava Rao Karicherla as Vice President – Formulation Research & Development, effective July 6, 2026.